Given the biological role of IL‐29 in many immune and non‐immune cells, including KCs, monocytes, pDC, B cells, mast cells and its regulatory ability in many autoimmune components, this cytokine may be considered as a therapeutic target for the complex inflammatory diseases such as OA and RA. Here, IFNL1 is linked to rheumatoid arthritis.